Metric Finance
LearnFAQ
LearnFAQ

Learn / SRZN

NASDAQ: SRZN

Surrozen, Inc./DE (SRZN) stock, explained like you're 5

Surrozen, Inc./DE trades on the Nasdaq under the ticker SRZN. It is a small cap company in the biological products (no diagnostic substances) industry, part of the healthcare sector, with a market value of about 349 million dollars.

Ticker
SRZN
Exchange
Nasdaq
Sector
Healthcare
Industry
Biological Products (No Diagnostic Substances)
Size
Small cap, about 349 million dollars

Is Surrozen, Inc./DE a small, medium or large cap company?

No. Surrozen, Inc./DE is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 349 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Surrozen, Inc./DE makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves SRZN stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • $SRZN stock is down 19% today. Here's what we see in our data. (Quiver Quantitative)
  • Understanding the Setup: (SRZN) and Scalable Risk (Stock Traders Daily)
  • Surrozen, Inc. Common Stock (SRZN) Stock Price: Oct 7 Close $25.15 (Gotrade)
  • Four parties report the same 1.36M share stake in Surrozen (SRZN). (Stock Titan)
  • Surrozen (SRZN) Jumps 5.56% to $25.07 as Biotech Name Tests Upper Range MA Crossover (https://www.siam.in/)

Follow SRZN in your daily brief

Each trading day at 5 PM ET we post what happened to Surrozen, Inc./DE and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow SRZN

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Surrozen, Inc./DE stock

What does Surrozen, Inc./DE do?

Surrozen, Inc./DE trades on the Nasdaq under the ticker SRZN. It is a small cap company in the biological products (no diagnostic substances) industry, part of the healthcare sector, with a market value of about 349 million dollars.

What is the ticker symbol for Surrozen, Inc./DE?

Surrozen, Inc./DE trades under the ticker SRZN on the Nasdaq.

What is Surrozen, Inc./DE's market cap?

Surrozen, Inc./DE is a small cap stock with a market cap of about 349 million dollars.

How does Surrozen, Inc./DE make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves SRZN stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow SRZN stock every day?

Add SRZN to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow SRZN daily

A free brief on Surrozen, Inc./DE and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • ARGX · Argenx SE
  • RVMD · Revolution Medicines
  • BNTX · BioNTech SE
  • EXEL · Exelixis

Similar stocks

  • ARGXArgenx SE
  • RVMDRevolution Medicines
  • BNTXBioNTech SE
  • EXELExelixis

Compare SRZN: SRZN vs ARGX, SRZN vs RVMD, SRZN vs BNTX

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed